CAMCEVI KIT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CAMCEVI KIT (CAMCEVI KIT).
Leuprolide, a GnRH agonist, suppresses pituitary gonadotropin release via receptor desensitization, reducing testicular and ovarian sex steroid production.
| Metabolism | Primarily hepatic; metabolized by peptidases to inactive metabolites. |
| Excretion | Leuprolide is primarily metabolized in the liver, and approximately 5% of the dose is excreted unchanged in urine. Less than 5% is excreted unchanged in feces via biliary elimination. |
| Half-life | The terminal elimination half-life of leuprolide after subcutaneous administration is approximately 3 hours, with a range of 2.6 to 3.8 hours. This short half-life requires continuous delivery for sustained clinical effect. |
| Protein binding | Leuprolide is approximately 43-49% bound to plasma proteins, primarily to albumin. |
| Volume of Distribution | The volume of distribution for leuprolide is about 27 L (0.33 L/kg for a 70 kg person), indicating distribution into total body water and some tissue binding. |
| Bioavailability | The subcutaneous formulation of CAMCEVI has an absolute bioavailability of approximately 90% compared to intravenous administration. |
| Onset of Action | Following subcutaneous injection of CAMCEVI, suppression of testosterone to castrate levels (≤50 ng/dL) is achieved within 4 weeks in the majority of patients, with maximal suppression typically by 4-6 weeks. |
| Duration of Action | CAMCEVI provides sustained release over 6 months, maintaining testosterone suppression at or below castrate levels for the duration of the dosing interval. Clinical effect (testosterone suppression) persists for up to 6 months after a single injection. |
| Molecular Weight | 1269.47 |
42 mg subcutaneously every 6 months.
| Dosage form | EMULSION |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No dose adjustment required for mild to moderate hepatic impairment; not studied in severe hepatic impairment. |
| Pediatric use | Safety and efficacy not established in pediatric patients. |
| Geriatric use | No specific dose adjustment recommended; use caution due to potential comorbidities and polypharmacy. |
| 1st trimester | Leuprolide (active component of CAMCEVI) is contraindicated in pregnancy; may cause fetal harm based on animal studies. Effective contraception must be used during treatment. |
| 2nd trimester | Contraindicated; continued use may disrupt pregnancy and cause fetal loss. |
| 3rd trimester | Contraindicated; risk of fetal harm and pregnancy disruption. |
Clinical note
Comprehensive clinical and safety monograph for CAMCEVI KIT (CAMCEVI KIT).
| Placental transfer | Leuprolide is expected to cross the placenta based on animal studies; human data limited but potential for fetal exposure. |
| Breastfeeding | Leuprolide is not indicated for use in women of reproductive potential; excretion in human milk unknown. Due to potential serious adverse reactions, breastfeeding should be discontinued during treatment and for at least 6 months after last dose. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to leuprolide acetate or any componentPregnancy
| Precautions | Initial flare: transient increase in testosterone may worsen prostate cancer symptoms (e.g., bone pain, ureteral obstruction)., Hyperglycemia and increased risk of diabetes., Cardiovascular risks: myocardial infarction, stroke, sudden cardiac death., QT prolongation risk., Seizures and convulsions., Pituitary apoplexy (rare)., Hypersensitivity reactions including anaphylaxis. |
| Food/Dietary | No clinically significant food interactions have been reported. Avoid grapefruit juice as it may theoretically affect hormone metabolism, though not specifically studied with leuprolide. |
Loading safety data…
| Lactation Rating | L5 (Contraindicated) |
| Teratogenic Risk | Pregnancy Category X. First trimester: High risk of major congenital malformations including cardiovascular and CNS defects. Second and third trimesters: Risk of fetal harm including delayed ossification and reduced fetal weight. Contraindicated in pregnancy. |
| Fetal Monitoring | Perform pregnancy test before initiation. Monitor for signs of pregnancy during therapy. If pregnancy occurs, discontinue drug and counsel regarding fetal risk. No specific fetal monitoring required beyond standard prenatal care. |
| Fertility Effects | May impair fertility in males and females due to hormonal suppression (leuprolide is a GnRH agonist). Reversible upon discontinuation. Consider fertility preservation options. |
| Clinical Pearls |
| CAMCEVI (leuprolide) is a GnRH agonist for advanced prostate cancer. Initial administration may cause transient testosterone surge (flare reaction), leading to increased bone pain, urinary obstruction, or spinal cord compression. Consider antiandrogen co-therapy (e.g., bicalutamide) for first 2-4 weeks to mitigate flare. Monitor serum testosterone and PSA levels. Injection site reactions are common; rotate sites. Use with caution in patients with a history of thromboembolic events. |
| Patient Advice | This medication is injected under the skin every 6 months by a healthcare provider. · You may experience a temporary worsening of symptoms (e.g., bone pain, difficulty urinating) during the first few weeks of treatment. · Report any new or worsening back pain, leg weakness, or difficulty urinating immediately. · Long-term use may cause hot flashes, decreased libido, erectile dysfunction, and loss of bone density. · Do not discontinue without consulting your doctor; withdrawal may lead to disease flare. · This drug does not cure prostate cancer but helps control its growth. |